The FDA’s advisory committee dealt a blow to the agency’s plan to ban compounded glutathione—but the fight is far from over. Action Alert! Earlier this week, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met to discuss whether it would recommend compounded glutathione be banned or not. As we reported that day, the great news is that PCAC voted 8-5 (with one abstention) NOT to ban glutathione. This is a significant victory for natural health and a testament to the power of ANH member and other stakeholder advocacy on this issue. Read more.